G-Glu-Val, also known as gamma-Glutamyl-L-valine or H-gGlu-Val-OH, is a taste-modulating dipeptide and a main contributor to the "kokumi" taste of edible beans.

MAK683 is a novel PRC2/EED inhibitor.

CO-1686 is a novel, irreversible and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M(IC50=21 nM).

DS-6051b is a potent and selective ROS1 and TRK family inhibitor with IC50 of 0.207 nM, 0.622 nM and 0.980 nM against ROS1, NTRK1 and NTRK3. DS-6051b especially inhibits ROS1 G2032R and other crizotinib-resistant ROS1 mutants.

BBO-11818 is an orally active, highly selective (relative to NRAS and HRAS), non-covalent pan-KRAS inhibitor (IC50=28-120 nM). BBO-11818 specifically binds to the Switch-II/Helix 3 pocket, disrupts the KRAS:RAF1 interaction by inducing conformational changes, and blocks the MAPK signaling pathway. BBO-11818 exhibits significant anti-tumor activity, which not only inhibits cell proliferation and induces apoptosis, but also drives tumor regression in xenograft models. BBO-11818 produces synergistic effects when combined with Cetuximab, anti-PD-1 antibody or PI3Kα inhibitor. BBO-11818 is used in the research of KRAS mutation-related malignancies such as pancreatic cancer, non-small cell lung cancer and colorectal cancer.

MMV009085 is a potent and selective inhibitor of the Plasmodium falciparum hexose transporter (PfHT1), designed to target malaria by blocking glucose uptake, with an IC50 of 2.6 μM for the transporter and an EC50 of 1.23 μM against the 3D7 strain. It acts as a probe-like molecule with high selectivity for PfHT1 over human glucose transporters (GLUTs). In vitro, it shows selective inhibition of Neospora caninum tachyzoite proliferation in infected host cell assays, with an IC₅₀ of approximately 150 ± 30 nM, while also displaying activity against related apicomplexan pathogens such as Cryptosporidium parvum. Mechanistically, related studies suggest MMV009085 may interfere with hexose transport–dependent metabolism, likely acting as a glucose transporter mimic or inhibitor, thereby disrupting parasite energy uptake and intracellular replication.

HDB-1 is a P2Y14R inhibitor for ameliorating liver fibrosis by suppressing hepatic stellate cell activation. HDB-1 demonstrates exceptional potency (IC50 = 0.026 nM) and superior metabolic stability. HDB-1 exhibited antihepatic fibrosis activity both in vivo and in vitro. Mechanistically, HDB-1 inhibits P2Y14R-mediated signaling by suppressing the PKA/Raf1/MEK/ERK cascade, thereby preventing the activation of hepatic stellate cells-the central pathological event in fibrosis development.

PROTAC BCL6 Degrader-3 (compound 92) is a BCL6 PROTAC degrader. PROTAC BCL6 Degrader-3 can be used for the study of cancer or an autoimmune disease.

UR778Br is a small-molecule inhibitor targeting the GTPase-activating protein–related (GRD) domain of IQGAP1, with demonstrated anti-leukemia activity in both in vitro and in vivo preclinical models. In human AML cell lines (e.g., MOLM13, MV4-11, THP-1, U937) and primary AML blasts, UR778Br shows dose-dependent suppression of proliferation (effective low-µM range), induces G2/M cell-cycle arrest, and triggers apoptosis.

JT71 is a small-molecule inhibitor of the bacterial transcription regulator MrkH, showing potent anti-biofilm and anti-virulence activity in both in vitro and in vivo-relevant infection models. In vitro, JT71 inhibits MrkH-mediated transcription of the mrkA operon and suppresses type 3 fimbriae production in Klebsiella pneumoniae, resulting in ~50% reduction of mrkA promoter activity at 50 μM without affecting bacterial viability. It significantly reduces biofilm formation across multiple clinical and multidrug-resistant K. pneumoniae isolates as well as Citrobacter koseri, and downregulates both mrkH and mrkA expression, confirming dual transcriptional suppression. Mechanistically, JT71 binds to MrkH and interferes with c-di-GMP–dependent activation and/or DNA-binding activity, disrupting fimbriae assembly and surface adhesion.

NSC73306 is a cell penetrant, cytotoxic agent that exhibits greater toxicity against cells expressing functional P-gp (P-glycoprotein) than against other cells. Irrespective of variations in cell line background, NSC73306 consistently demonstrated a Pgp-potentiated MDR-selective toxicity.

HBC599 is a HBC analog. HBC is nonfluorescent in solution, but emits strong fluorescence upon forming tight complex with Pepper RNA aptamer. HBC-Pepper complex can be used to visualize RNA dynamics in live cells.

Natamycin is a naturally occurring polyene macrolide antifungal agent produced by Streptomyces natalensis, exhibiting potent in vitro and in vivo activity against a broad spectrum of yeasts and filamentous fungi. In vitro studies show strong inhibition of Candida spp., Aspergillus spp., and other food- and ocular-relevant fungi, with reported MIC values typically in the low µg/mL range (often ~1–10 µg/mL depending on species and strain).

Tri-b-GalNAc-b-Ala-PEG3-MAL contains three terminal beta-N-acetylgalactosamine (GalNAc) sugars arranged in a trivalent configuration, facilitating high-affinity binding to the asialoglycoprotein receptor (ASGPR) expressed on hepatocyte surfaces. The crucial functional group is a terminal maleimide (MAL) moiety, enabling chemoselective bioconjugation with biomolecules harboring thiol (-SH) groups. This strategy allows for site-specific conjugation under mild conditions, valuable for developing targeted conjugates in disciplines like targeted drug delivery and antibody-drug conjugate (ADC) development for hepatocellular carcinoma.

6Ac1-C12 is an ionizable cationic lipid with a hexaester degradable core and six C12 hydrophobic alkyl tails, featuring a pKa around 6.0 and strong endosomal escape capacity. Its four-component LNPs deliver mRNA mainly to liver endothelial cells after IV injection and remain stable for 30 days at 4°C. Formulated without cholesterol, its three-component system enables lung-targeted delivery with low in vivo toxicity, and the ester core facilitates biodegradation for versatile mRNA applications.

Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis.

dIRF4-2 is a first-in-class proteolysis-targeting chimera of IRF4, by linking (S)-H1 to E3 ligase ligands of cereblon. dIRF4-2 achieves highly selective IRF4 knockdown (DC50 ~2.2–2.3 µM) without degrading off-target neosubstrates such as IKZF1/3 or GSPT1, and demonstrates strong cytotoxic effects across all multiple myeloma cell lines tested in vitro.

dHuR-2 is the optimized analogue of dHuR-1 and exhibits exceptional nanomolar potency (DC50=3.8 nM) and oral bioavailability, effectively suppressing BRAF-mutant colorectal cancer by inducing unique BRAF mRNA exon skipping and overcoming existing inhibitor resistance.

dHuR-1 is the first-in-class molecular glue degrader that recruits the CRBN E3 ligase to selectively eliminate the oncogenic RNA-binding protein HuR.

Ganaxolone, also known as CCD 1042 and C1042, is a CNS-selective GABAA modulator that acts on well-characterized targets in the brain known to have anxiolytic and anticonvulsant effects. Ganaxolone protects against seizures in diverse animal models, including the pentylenetetrazol, 6 Hz and amygdala kindling models. Ganaxolone is a positive allosteric modulator of the action of the GABAA receptor and, unlike benzodiazepines, there does not appear to be tolerance to the anticonvulsant effects of ganaxolone.

SBI-810 hydrochloride is a functionally selected β-arrestin-biased neurotensin receptor 1 (NTSR1) allosteric modulator. SBI-810 hydrochloride modulates NTSR1 G protein signaling in a G protein-specific manner in the presence of the endogenous ligand, neurotensin (NT). SBI-810 hydrochloride fully antagonizes NT-induced activation of Gq, partially antagonizes NT-induced activation of Gi1 and is permissive of NTSR1 activation of GoA and G12.

SBI-810 is a functionally selected β-arrestin-biased neurotensin receptor 1 (NTSR1) allosteric modulator. SBI-810 modulates NTSR1 G protein signaling in a G protein-specific manner in the presence of the endogenous ligand, neurotensin (NT). SBI-810 fully antagonizes NT-induced activation of Gq, partially antagonizes NT-induced activation of Gi1 and is permissive of NTSR1 activation of GoA and G12.

KOTX1 is a potent, selective and reversible ALDH1A3 inhibitor with IC50 of 5.14 nM by Aldefluor assay in A375 cells.

TXX-1-10 (CB1-8) is a small chemical molecule that inhibits HPIP oncoprotein expression, suppresses breast cancer cell growth and metastasis in vitro and in vivo.

113-AA-C8C14 is a spleen-tropic ionizable lipid with inherent splenic organ selectivity. Its formulated LNPs drastically reduce off-target liver uptake and drive 57-fold higher mRNA expression in spleen versus benchmark LNPs. It preferentially delivers nucleic acids to splenic immune cells like macrophages and T lymphocytes, supporting in vivo CAR-T engineering and mRNA vaccine research with minimal accumulation in other visceral organs.

RN277 is an inhibitor for LRRK2 type II kinase. RN277 can be used as a cellular tool targeting the LRRK2 inactive state. RN277 can inhibit LRRK1 kinase activity in vitro. RN277 inhibits LRRK2 kinase activity in vitro (IC50 = 70 nM). RN277 reduces phosphorylation of Rab8a dose-dependently. RN277 can be studied in research for Parkingson’s disease.

RN341 is a specific type II kinase inhibitor of LRRK2 (IC50: 296 nM). RN341 inhibits LRRK2 phosphorylation and avoids S935 dephosphorylation by stabilizing the open conformation. RN341 rescues LRRK2-mediated kinesin motility block by preventing microtubule binding. RN341 effectively inhibits LRRK2 wild-type and G2019S mutant at the cellular level. RN341 provides a new direction for Parkinson's disease research.